587 research outputs found
Recommended from our members
Construction and testing of an 11.4 GHz dielectric structure based travelling wave accelerator
One major challenge in constructing a dielectric loaded traveling wave accelerator powered by an external rf power source is the difficulty in achieving efficient coupling. In this paper, we report that we have achieved high efficiency broadband coupling by using a combination of a tapered dielectric section and a carefully adjusted coupling slot. We are currently constructing an 11.4 GHz accelerator structure loaded with a permitivity=20 dielectric. Bench testing has demonstrated a coupling efficiency in excess of 95% with bandwidth of 600 MHz. The final setup will be tested at high power at SLAC using an X-band klystron rf source
Accurate Relativistic Real-Time TDDFT for Valence and Core Attosecond Transient Absorption Spectroscopy
Attosecond pump-probe transient absorption spectroscopy (TAS) has opened the possibility to study pure electron dynamics on its natural time scale. However, due to the out-of-equilibrium nature of the process, first-principle theoretical modelling remains a challenging task, specially for heavy elements and/or core excitations where relativistic corrections become imperative, as the spectra contain significant imprints of both scalar and spin-orbit relativistic effects. To alleviate this problem, we formulated a methodology for computing TAS spectrum within the relativistic real-time time-dependent density functional theory (RT-TDDFT) framework, for both the valence and core energy regime. Even though RT simulations using full four-component (4c) method are feasible, they are still computationally expensive, especially for TAS. Therefore, in addition to the 4c approach, we have introduced the atomic mean-field exact two-component (amfX2C) Hamiltonian for RT-TDDFT, which accounts for one- and two-electron picture-change corrections and preserves the accuracy of the parent 4c method but at a fraction of its computational cost. Finally, we apply the amfX2C approach to study valence and near L 2,3 -edge TAS processes of experimentally relevant systems, providing additional physical insights through the lens of non-equilibrium response theory
Observations of Microwave Continuum Emission from Air Shower Plasmas
We investigate a possible new technique for microwave measurements of
ultra-high energy cosmic ray (UHECR) extensive air showers which relies on
detection of expected continuum radiation in the microwave range, caused by
free-electron collisions with neutrals in the tenuous plasma left after the
passage of the shower. We performed an initial experiment at the AWA (Argonne
Wakefield Accelerator) laboratory in 2003 and measured broadband microwave
emission from air ionized via high energy electrons and photons. A follow-up
experiment at SLAC (Stanford Linear Accelerator Center) in summer of 2004
confirmed the major features of the previous AWA observations with better
precision and made additional measurements relevant to the calorimetric
capabilities of the method. Prompted by these results we built a prototype
detector using satellite television technology, and have made measurements
indicating possible detection of cosmic ray extensive air showers. The method,
if confirmed by experiments now in progress, could provide a high-duty cycle
complement to current nitrogen fluorescence observations of UHECR, which are
limited to dark, clear nights. By contrast, decimeter microwave observations
can be made both night and day, in clear or cloudy weather, or even in the
presence of moderate precipitation.Comment: 15 pages, 13 figure
The role of electronic correlation in the Si(100) reconstruction: a quantum Monte Carlo study
Recent low-temperature scanning tunneling experiments have challenged the
generally accepted picture of buckled silicon dimers as the ground state
reconstruction of the Si(100) surface. Together with the symmetric dimer model
of the surface suggested by quantum chemistry calculations on small clusters,
these findings question our general understanding of electronic correlations at
surfaces and its proper description within density functional theory. We
present quantum Monte Carlo calculations on large cluster models of the
symmetric and buckled surface, and conclude that buckling remains energetically
more favorable even when the present-day best treatment of electronic
correlation is employed.Comment: 5 pages, Revtex, 10 figure
Radio-Frequency Measurements of Coherent Transition and Cherenkov Radiation: Implications for High-Energy Neutrino Detection
We report on measurements of 11-18 cm wavelength radio emission from
interactions of 15.2 MeV pulsed electron bunches at the Argonne Wakefield
Accelerator. The electrons were observed both in a configuration where they
produced primarily transition radiation from an aluminum foil, and in a
configuration designed for the electrons to produce Cherenkov radiation in a
silica sand target. Our aim was to emulate the large electron excess expected
to develop during an electromagnetic cascade initiated by an ultra high-energy
particle. Such charge asymmetries are predicted to produce strong coherent
radio pulses, which are the basis for several experiments to detect high-energy
neutrinos from the showers they induce in Antarctic ice and in the lunar
regolith. We detected coherent emission which we attribute both to transition
and possibly Cherenkov radiation at different levels depending on the
experimental conditions. We discuss implications for experiments relying on
radio emission for detection of electromagnetic cascades produced by ultra
high-energy neutrinos.Comment: updated figure 10; fixed typo in equation 2.2; accepted by PR
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
In this study, we explore the therapeutic potential of lapatinib a selective inhibitor of both the EGFR and HER2 tyrosine kinases for the treatment of endometrial cancer. The effect of lapatinib on tumour cell growth and receptor activation was studied in a panel of human endometrial cancer cell lines. Candidate molecular markers predicting sensitivity were assessed by baseline gene expression profiling, ELISA, and western blot analyses. Multiple drug effect/combination index (CI) isobologram analysis was used to study the interactions between chemotherapeutic drugs and lapatinib. Concentration-dependent anti-proliferative effects of lapatinib were seen in all endometrial cancer cell lines tested, but varied significantly between individual cell lines (IC50 range: 0.052–10.9 μmol). HER2 overexpression or increased expression of EGFR was significantly associated with in vitro sensitivity (P=0.024 or 0.011, respectively). Lapatinib exerts growth inhibition in a PTEN-independent manner. Sensitive cell lines also exhibited increased expression of EGFR ligands or HER3. In contrast, lapatinib-resistant cell lines exhibited high androgen receptor (AR) levels or epithelial-to-mesenchymal transition (post-EMT) features. In endometrial cancer cells, at a wide range of clinically achievable drug concentrations, additive and synergistic interactions were observed for lapatinib plus carboplatin, paclitaxel, docetaxel, and doxorubicin. These observations provide a clear biologic rational to test lapatinib as a single agent or in combination with chemotherapy in endometrial cancer with HER2 overexpression. Expression of EGFR, its ligands, HER3, AR, and post-EMT markers warrant further evaluation to help define patients with HER2-nonoverexpressing endometrial cancer most likely to benefit from lapatinib
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma
BACKGROUND: We wished to evaluate the clinical response following ATP-Tumor Chemosensitivity Assay (ATP-TCA) directed salvage chemotherapy in a series of UK patients with advanced ovarian cancer. The results are compared with that of a similar assay used in a different country in terms of evaluability and clinical endpoints. METHODS: From November 1998 to November 2001, 46 patients with pre-treated, advanced ovarian cancer were given a total of 56 courses of chemotherapy based on in-vitro ATP-TCA responses obtained from fresh tumor samples or ascites. Forty-four patients were evaluable for results. Of these, 18 patients had clinically platinum resistant disease (relapse < 6 months after first course of chemotherapy). There was evidence of cisplatin resistance in 31 patients from their first ATP-TCA. Response to treatment was assessed by radiology, clinical assessment and tumor marker level (CA 125). RESULTS: The overall response rate was 59% (33/56) per course of chemotherapy, including 12 complete responses, 21 partial responses, 6 with stable disease, and 15 with progressive disease. Two patients were not evaluable for response having received just one cycle of chemotherapy: if these were excluded the response rate is 61%. Fifteen patients are still alive. Median progression free survival (PFS) was 6.6 months per course of chemotherapy; median overall survival (OAS) for each patient following the start of TCA-directed therapy was 10.4 months (95% confidence interval 7.9-12.8 months). CONCLUSION: The results show similar response rates to previous studies using ATP-TCA directed therapy in recurrent ovarian cancer. The assay shows high evaluability and this study adds weight to the reproducibility of results from different centre
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Background:
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma.
Methods:
In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concentration of less than the upper limit of normal, had a performance status of 0–1, and had adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous system metastases, had received anticancer therapy 14 days or fewer before starting the study, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor. We randomly allocated patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28 day cycles using a computer-generated sequence (block size of six, stratified by homologous recombination repair gene mutation status, progression-free interval after the penultimate platinum-based regimen, and best response to the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary outcome was investigator-assessed progression-free survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), patients with homologous recombination deficiencies (BRCA mutant or BRCA wild-type and high loss of heterozygosity), and the intention-to-treat population, assessed at screening and every 12 weeks thereafter. This trial is registered with ClinicalTrials.gov, number NCT01968213; enrolment is complete.
Findings:
Between April 7, 2014, and July 19, 2016, we randomly allocated 564 patients: 375 (66%) to rucaparib and 189 (34%) to placebo. Median progression-free survival in patients with a BRCA-mutant carcinoma was 16·6 months (95% CI 13·4–22·9; 130 [35%] patients) in the rucaparib group versus 5·4 months (3·4–6·7; 66 [35%] patients) in the placebo group (hazard ratio 0·23 [95% CI 0·16–0·34]; p<0·0001). In patients with a homologous recombination deficient carcinoma (236 [63%] vs 118 [62%]), it was 13·6 months (10·9–16·2) versus 5·4 months (5·1–5·6; 0·32 [0·24–0·42]; p<0·0001). In the intention-to-treat population, it was 10·8 months (8·3–11·4) versus 5·4 months (5·3–5·5; 0·36 [0·30–0·45]; p<0·0001). Treatment-emergent adverse events of grade 3 or higher in the safety population (372 [99%] patients in the rucaparib group vs 189 [100%] in the placebo group) were reported in 209 (56%) patients in the rucaparib group versus 28 (15%) in the placebo group, the most common of which were anaemia or decreased haemoglobin concentration (70 [19%] vs one [1%]) and increased alanine or aspartate aminotransferase concentration (39 [10%] vs none).
Interpretation:
Across all primary analysis groups, rucaparib significantly improved progression-free survival in patients with platinum-sensitive ovarian cancer who had achieved a response to platinum-based chemotherapy. ARIEL3 provides further evidence that use of a poly(ADP-ribose) polymerase inhibitor in the maintenance treatment setting versus placebo could be considered a new standard of care for women with platinum-sensitive ovarian cancer following a complete or partial response to second-line or later platinum-based chemotherapy.
Funding:
Clovis Oncology
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas from patients treated within the neoadjuvant GeparQuattro trial.
Methods: HER2 levels were centrally analyzed by immunohistochemistry (IHC), silver in-situ hybridization (SISH) and qRT-PCR in 217 pretherapeutic formalin-fixed, paraffin-embedded (FFPE) core biopsies. All tumors had been HER2-positive by local pathology and had been treated with neoadjuvant trastuzumab/ chemotherapy in GeparQuattro.
Results: Only 73% of the tumors (158 of 217) were centrally HER2-positive (cHER2-positive) by IHC/SISH, with cHER2-positive tumors showing a significantly higher pCR rate (46.8% vs. 20.3%, p<0.0005). HER2 status by qRT-PCR showed a concordance of 88.5% with the central IHC/SISH status, with a low pCR rate in those tumors that were HER2-negative by mRNA analysis (21.1% vs. 49.6%, p<0.0005). The level of HER2 mRNA expression was linked to response rate in ESR1-positive tumors, but not in ESR1-negative tumors. HER2 mRNA expression was significantly associated with pCR in the HER2-positive/ESR1-positive tumors (p=0.004), but not in HER2-positive/ESR1-negative tumors.
Conclusions: Only patients with cHER2-positive tumors - irrespective of the method used - have an increased pCR rate with trastuzumab plus chemotherapy. In patients with cHER2-negative tumors the pCR rate is comparable to the pCR rate in the non-trastuzumab treated HER-negative population. Response to trastuzumab is correlated to HER2 mRNA levels only in ESR1-positive tumors. This study adds further evidence to the different biology of both subsets within the HER2-positive group
Artificial intelligence and visual analytics in geographical space and cyberspace: Research opportunities and challenges
In recent decades, we have witnessed great advances on the Internet of Things, mobile devices, sensor-based systems, and resulting big data infrastructures, which have gradually, yet fundamentally influenced the way people interact with and in the digital and physical world. Many human activities now not only operate in geographical (physical) space but also in cyberspace. Such changes have triggered a paradigm shift in geographic information science (GIScience), as cyberspace brings new perspectives for the roles played by spatial and temporal dimensions, e.g., the dilemma of placelessness and possible timelessness. As a discipline at the brink of even bigger changes made possible by machine learning and artificial intelligence, this paper highlights the challenges and opportunities associated with geographical space in relation to cyberspace, with a particular focus on data analytics and visualization, including extended AI capabilities and virtual reality representations. Consequently, we encourage the creation of synergies between the processing and analysis of geographical and cyber data to improve sustainability and solve complex problems with geospatial applications and other digital advancements in urban and environmental sciences
- …